Your browser doesn't support javascript.
loading
Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies.
Haak, Andrew J; Ducharme, Merrick T; Diaz Espinosa, Ana M; Tschumperlin, Daniel J.
Afiliação
  • Haak AJ; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA. Electronic address: haak.andrew@mayo.edu.
  • Ducharme MT; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
  • Diaz Espinosa AM; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
  • Tschumperlin DJ; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Trends Pharmacol Sci ; 41(3): 172-182, 2020 03.
Article em En | MEDLINE | ID: mdl-32008852
ABSTRACT
A variety of G protein-coupled receptors (GPCRs) have been implicated in the pathogenesis of pulmonary fibrosis, largely through their promotion of profibrotic fibroblast activation. By contrast, recent work has highlighted the beneficial effects of Gαs-coupled GPCRs on reducing fibroblast activation and fibrosis. This review highlights how fibrosis-promoting and -inhibiting GPCR signaling converges on downstream signaling and transcriptional effectors, and how the diversity and dynamics of GPCR expression challenge efforts to identify effective therapies for idiopathic pulmonary fibrosis (IPF). Next-generation strategies to overcome these challenges, focusing on target selection, polypharmacology, and personalized medicine approaches, are discussed as a path towards more effective GPCR-targeted therapies for pulmonary fibrosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar Idiopática Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar Idiopática Idioma: En Ano de publicação: 2020 Tipo de documento: Article